Neuroblastoma Research and Treatments

Moving in bioRxiv, Cancer Research, Frontiers in Genetics, Cell Reports, Nature Communications and Nature Medicine.

Moved, week to 23 Oct 2026: 0
Papers in 60 days: 12

Add Neuroblastoma Research and Treatments as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest

Rebuilt 23 October 2026 at 1:59 pm AEDT

Moved this week

Everything that moved →

Nothing in this topic has moved yet this week.

Latest in Neuroblastoma Research and Treatments

Newest first · last 60 days

Gene Regulatory Network Inference reveals tcf4 as a key a player in neuroblastoma gene expression circuitry
bioRxiv · 12 Oct 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.07.07.737136
Open in JClub
Pharmacologically targeting CDK12 induces BRCAness and synergizes with merestinib to exacerbate DNA damage in high-risk neuroblastoma.
Cell Reports · 12 Oct 2026 · Journal Article
Inhibition of CDK12 induces BRCAness and apoptosis in neuroblastoma cells, with OKI-1546 reducing tumor growth and extending survival in vivo.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42867993
Open in JClub
AP-1 Primes Transcriptional Noise-Led Cancer Treatment Adaptation Through KDM5 Chromatin Rewiring
bioRxiv · 7 Oct 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2025.10.13.682004
Open in JClub
Longitudinal single-cell analysis identifies a chemotherapy-suppressed proliferative program associated with adverse prognosis in neuroblastoma.
Frontiers in Genetics · 2 Oct 2026 · Journal Article
A chemotherapy-suppressed proliferative program in malignant neuroblasts predicts adverse prognosis in neuroblastoma.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42890550
Open in JClub
From Tissue Specificity to Systemic Cues: Shaping MYC-Driven Tumor Metabolism.
Cancer Research · 2 Oct 2026 · Review
MYC-driven tumor metabolism varies with tissue type, microenvironment, and systemic factors, revealing context-dependent vulnerabilities that may inform targeted therapies.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42446901
Open in JClub
The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.
Cancer Research · 2 Oct 2026 · Journal Article
The ITCC-P4 platform established 353 molecularly characterized pediatric cancer PDX models for in vivo drug testing, capturing tumor heterogeneity and disease progression.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42430560
Open in JClub
Cumate-inducible models of MYC-driven neuroblastoma identify mitoribosomal synthetic lethality as a precision oncology vulnerability in MYC(N)-amplified tumors
bioRxiv · 1 Oct 2026 · Preprint
Mitoribosomal synthetic lethality is a vulnerability in MYC(N)-amplified neuroblastoma, with MYC activation sensitizing cells to mitochondrial ribosome inhibitors.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.05.25.725359
Open in JClub
ACTL6A regulates the Warburg effect through coordinated activation of AP-1 signaling in head and neck squamous cell carcinoma
bioRxiv · 1 Oct 2026 · Preprint
ACTL6A drives hypoxic adaptation and glycolysis in head and neck squamous cell carcinoma by activating AP-1 signaling and chromatin remodeling, with a critical role in tumor metabolism.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2025.09.02.671886
Open in JClub
A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.
Cancer Research · 15 Sept 2026 · Journal Article
A pediatric patient-derived xenograft (PDX) program created 388 models across 40+ diagnoses, including ultra-rare tumors, enabling detailed cancer biology and therapy studies.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42391326
Open in JClub
Loss of lactate dehydrogenase A disrupts R-loop homeostasis and induces DNA damage in breast cancer cells.
Frontiers in Genetics · 14 Sept 2026 · Journal Article
Loss of LDHA disrupts R-loop homeostasis and induces DNA damage in breast cancer cells, with 199 peaks increased and 81 decreased in 4T1 cells.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42802879
Open in JClub
CpG hypermethylation and WNT/AP-1 cooperativity define the epigenetic landscape and a clinical subgroup of high-risk pediatric adrenocortical carcinoma.
Nature Communications · 14 Sept 2026 · Journal Article
CpG island hypermethylation and WNT/AP-1 activation define a high-risk subgroup with poor prognosis in pediatric adrenocortical carcinoma.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42736301
Open in JClub
An anti-PMEL antibody-drug conjugate with a G(q/1)(1) inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.
Nature Medicine · 1 Sept 2026 · Clinical Trial, Phase I
DYP688, an antibody-drug conjugate targeting PMEL with a Gq/11 inhibitor payload, shows promising activity in GNAQ/GNA11-mutant melanomas with a 19.7% response rate.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42443515
Open in JClub

Add Neuroblastoma Research and Treatments as an interest in JClub

Journals this month

All journals →

Topics moving, week to 23 Oct 2026

All topics →

By field

All journals by field →

Moved this week

Latest in Neuroblastoma Research and Treatments

Browse JClub